Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KM602
- Development stage
- Phase 1
- Lead developer
- Xuanzhu Biopharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
KM602 is a recombinant fusion protein composed of the extracellular domain of human CD80 (B7.1) fused to a human immunoglobulin G1 (IgG1) Fc fragment. It is being developed as an antineoplastic agent with potential immunostimulatory and immune checkpoint inhibitory activities. The drug is designed to modulate immune responses against tumors by targeting pathways involved in T cell activation and immune evasion. Its primary indication under investigation is for advanced solid tumors, including inoperable or metastatic disease settings[1][2][3][4][5].
- Other names
- CD80-Fc fusion protein KM602CD-80-Fc fusion protein KM602CD 80-Fc fusion protein KM602recombinant human CD80 mutant-Fc fusion protein
02
Targets
CD28 (Cluster of Differentiation 28)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on KM602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KM602.